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Abstract 
Objective: Influenza virus, which is associated with high level of 
morbidity and mortality, has been recently considered a public 
health concern; however, the methods of choice to control and treat 
it are limited. Our previous study showed anti-influenza virus 
activity of pomegranate peel extract (PPE). In this study, the 
mechanism through which PPE acts against influenza virus 
A/Puerto Rico/8/34 (H1N1; PR8) was investigated.  
Materials and Methods: Ethyl alcohol extract of pomegranate 
(Punica granatum L.) peel was prepared, and the action mechanism 
of PPE in inhibiting influenza replication was studied by time-of-
drug-addition assay, virucidal activity, RNA replication, 
hemagglutination inhibition assay, viral mRNA expression, and 
western blot analysis.  
Results: PPE inhibited viral polymerase activity, viral RNA 
replication, and viral protein expression but could not affect 
hemagglutination inhibition and virucidal activity. According to 
time-of-drug-addition assay results, PPE inhibited the virus 
adsorption and early steps of influenza replication.  
Conclusion: This study demonstrated that the antiviral effect of 
PPE on influenza virus is most probably associated with inhibition 
of viral adsorption and viral RNA transcription.  
Please cite this paper as:  
Moradi MT, Karimi A, Rafieian-kopaei M, Rabiei-Faradonbeh M, Momtaz H. Pomegranate peel extract inhibits 
internalization and replication of the influenza virus: An in vitro study. Avicenna J Phytomed, 2020; 10(2): 143-
151.
Introduction 
As an emerging public health issue, 
influenza virus is one of the most prevalent 
causes of respiratory tract infection that leads 
to high morbidity and mortality rates in 
humans. Annual vaccination is the main 
approach to prevent influenza infection. 
Anti-influenza drugs are also useful to 
prevent and treat the infection (Hayden, 
2006). Currently, there are three groups of 
anti-influenza agents to fight influenza 
infection: 1- Amantadine and rimantadine 
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are matrix protein (M2) ion-channel 
inhibitors that interfere with intracellular 
viral uncoating in the host. These are 
effective only against influenza virus A but 
have widely acquired resistance to it; 2- 
neuraminidase (NA) inhibitors such as 
oseltamivir and zanamivir are widely used to 
treat seasonal and pandemic influenza virus 
infections (Jackson et al., 2011); and 3- cap-
dependent endonuclease inhibitor such as 
baloxavir marboxil (CDC, 2018). However, 
oseltamivir-resistant H1N1 strains have 
spread since 2007–2008 (Dapat et al., 2013; 
Van Der Vries et al., 2013). Because of the 
constant risk of the emergence of antiviral-
resistant influenza strains, it is important to 
consistently seek out drugs that could be used 
to prevent and treat influenza. As there are 
few approaches to control and treat this 
infection, plant extracts including 
pomegranate peel extract (PPE) can be a 
treatment of choice.  
Pomegranate (Punica granatum L., from 
family Punicaceae) is one of the oldest 
edible fruits that is cultivated in many 
countries (Elyatem Kader, 1984). It is 
extensively cultivated in Iran, Egypt, Russia, 
Spain, France, China, Japan, Argentina, 
USA, and India. Pomegranate is extensively 
used in the folk medicine of Iran and many 
other countries. Many studies have indicated 
the therapeutic efficacy of pomegranate 
against different types of disorders 
(Ibrahium, 2010; Haber et al., 2011; Ismail 
et al., 2012; Colombo et al., 2013; Asmaa et 
al., 2015).  
Although pomegranate peel is 
sometimes considered an agro-waste, it is 
indeed a source of different flavonoids such 
as kaempferol, kaempferolerol-3-O-
glucoside, epicatechin, catechin, 
epigallocatechin-3-gallate, flavan-3-ol, 
kaempferol-3-O-rhamnoglycoside, luteolin 
7-Oglucoside, luteolin, naringin, 
pelargonidin, prodelphindin, quercetin, and 
rutin with reported antiviral, antibacterial, 
anti-inflammatory, antioxidant, and 
antineoplastic bioactivities (Plumb et al., 
2002; Lansky Newman, 2007). Our previous 
study showed that PPE had interesting 
antiviral activity against Influenza virus in 
MDCK cells (Moradi et al., 2017). The aim 
of this study was to investigate the action 
mechanism of PPE against Influenza A/PR/8 
virus in MDCK cells.  
 
 
Materials and Methods 
Plant collection and extraction 
The pomegranate (Punica granatum L.) 
used in this study was from the Malas 
variety obtained from Shahreza, a central 
region of Iran. The peel powder was 
dissolved in 80% ethanol and kept at room 
temperature for 96 hr. Next, the mixture 
was filtered and concentrated under nearly 
vacuum pressure at 40°C in a rotary 
evaporator.  
 
Cell culture and influenza virus 
propagation 
Influenza virus A/Puerto Rico/8/34 
(H1N1; PR8) and Madin Darby Canine 
Kidney (MDCK) cell line were provided 
from the Influenza Unit of Pasteur Institute 
of Iran. MDCK cells were grown in 
Dulbecco’s Modified Eagle’s Medium 
(DMEM, Gibco, USA) with 10% fetal 
bovine serum (FBS, Gibco, USA), 100 
U/ml penicillin, and 10 μg/ml streptomycin 
(Pen/Strep, Gibco, USA) at 37ºC in a 
humidified incubator with 5% CO2. 
 
Virus titration 
A standard 50% tissue culture infectious 
dose (TCID50) method was applied for virus 
titration (Kim et al., 2010). At 90% 
confluence, MDCK cells were prepared in 
96-well plates, the cell culture medium was 
aspirated and washed twice with phosphate-
buffered saline (PBS). Then, 200 μl of 10-
fold dilutions of virus in DMEM with 0.5 
μg/ml trypsin TPCK was added into the 
wells and incubated for 2 days. Afterwards, 
50 μl of culture medium was taken from 
each well and transferred to a U-bottomed 
96-well plate for hemagglutination assay 
(WHO, 2011). TCID50 was calculated by 
the method of Reed and Muench (Reed and 
Muench, 1938).  
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Cytotoxicity assay 
The effect of PPE on the viability of 
MDCK cells was determined using 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-
diphenyltetrazoliumbromide (MTT, Sigma, 
USA) assay according to a previously 
described method (Mosmann, 1983) with 
some modifications. Briefly, when the cell 
monolayer was confluent, the cells were 
incubated with 200 µl/well of various 
concentrations of the extract in 96-well 
plates for 48 hr. Then, cell monolayers were 
incubated with 50 μl of 1 mg/ml MTT in 
PBS at 37°C for 4 hr and treated with 100 
μl of acidic isopropanol (0.05 NHCl in 
absolute isopropanol). Afterwards, the 
plates were shaken for 15 min, the 
absorbance was read using a reference filter 
at 640 nm wavelength using a microplate 
reader (StataFax2100, USA). 
 
Time-of-drug-addition assay 
To determine the stage of the viral life 
cycle that is affected by the PPE, MDCK 
cells were seeded into 24-well plates and 
incubated overnight until 90% confluence 
was achieved. Next, the cells were 
incubated with 104 TCID50 of the virus for 
1 hr at 37ºC, and washed with PBS, and 
then fresh medium containing TPCK and 
maximum non-toxic concentration (30 
µg/ml) of PPE was added. The PPE was 
added before the adsorption of the virus (-2 
to -1 hr), at adsorption (-1 to 0 hr) and at 
three time points post adsorption (0-2, 2-4, 
and 4–8 hr). After 8 hr incubation, 
supernatants were taken and virus progeny 
yield was determined using TCID50 assay 
(Matusevich et al., 2015; Zarubaev et al., 
2015). In brief, when 90% confluence was 
achieved, MDCK cells were prepared in 96-
well plates, the cell culture medium was 
aspirated and washed two times with PBS; 
then, 100 μl of a series of 10-fold dilutions 
was added to the wells and left to incubate 
for 2 days. After 48-hr incubation, virus 
replication was investigated by 
hemagglutination assay (Kim et al., 2010; 
Organization, 2011; Matusevich et al., 
2015). TCID50 (log10) was calculated by 
the method of Reed and Muench (Reed and 
Muench, 1938). 
 
Virucidal activity 
Maximum non-toxic dilution (30 µg/ml) 
of PPE and PBS was incubated with 104 
TCID50 of the virus for 1 hr at room 
temperature. Then, the infectious titer of the 
virus was determined using TCID50 assay 
(Matusevich et al., 2015). 
 
Inhibition of viral mRNA expression and 
viral RNA synthesis 
Confluent MDCK cells were infected 
with the virus and treated with different 
concentrations (30, 10, and 3 µg/ml) of the 
extract in 12-well plates for 13 hr (He et al., 
2011). Total RNA was extracted from the 
MDCK cells that were inoculated with 
either untreated or treated viruses by Trizol 
(Invitrogen, Waltham, MA, USA) based on 
the manufacturer’s instructions. The 
extracted RNA was transcribed into cDNA 
using RevertAid First Strand cDNA 
synthesis kit (Thermo Scientific, Lithuania) 
including an influenza A viral RNA-
specific universal primer from Uni12 
primers (5’-AGCAAAAGCAGG-3’) to 
detect viral RNA (vRNA) or oligo-dT 
primers to detect viral mRNA (vmRNA), 
RNase inhibitor, 5X Reaction buffer, and 
dNTP Mix to a final volume of 20 μl. Real-
time PCR was conducted to detect the 
vRNA and vmRNA. The vmRNA and 
vRNA levels were quantified by a 
RotorGene Q (Corbett, Qiagen, Germany) 
containing 1 μl of synthesized cDNA 
solution, 5 μl of 2X SYBER Green Master 
Mix (Thermo scientific, Lithuania), and 
500 nM of each primer (Table 1) to a final 
volume of 10 μl. Amplification protocol 
consisted of denaturation at 95ºC for 10 min 
followed by 45 cycles at 95ºC for 15 sec, 
72ºC for 25 sec and, and 54 or 58ºC for 20 
sec. Next, the specificity of the amplified 
products was confirmed with reference to 
melting curve analysis. All the reactions 
were performed in two independent repeats 
in duplicate. 
Moradi et al. 
AJP, Vol. 10, No. 2, Mar-Apr 2020                                                   146 
Table 1. Primers used in real-time RT-PCR. 
 
Gene name Primer sequence Melt temperature (oC) Product length (bp) 
Nucleocapsid protein (NP) 
F:TGTGTATGGACCTGCCGTAGC 
R:CCATCCACACCAGTTGACTCTTG 
62.1 
61.3 
158 
Hemagglutinin (HA) 
F:CCTGCTCGAAGACAGCCACAACG 
R:TTCCCAAGAGCCATCCGGCGA 
60.6 
58.3 
98 
Nonstructural protein (NS1) 
F:CATAATGGATCCAAACACTGTGTC 
R:CCTCTTAGGGATTTCTGATCTCGG 
58.1 
60 
138 
Matrix protein (M) 
F: GGCAAATGGTACAGGCAATG 
R: AGCAACGAGAGGATCACTTG 
57.7 
57.6 
144 
GAPDH 
F: GGAGAAAGCTGCCAAATATGACGA 
R: CGAAGGTGGAAGAGTGGGTGT 
61.4 
61.9 
140 
 
GAPDH: Canis lupus familiaris glyceraldehyde-3-phosphate dehydrogenase 
 
A mixture without cDNA template was 
used as negative control. The expression of 
mRNA was normalized against that of the 
control housekeeping gene (GAPDH) and 
the relative changes in gene expression 
were calculated using the relative 
quantitative method (2-ΔΔCt). The effects on 
viral RNA synthesis were calculated by 
absolute quantification and represented as 
log10 copy number decrements in 
treatments. 
 
Construction of the plasmid standards 
for quantification  
For quantification of real-time PCR 
assay, the amplified M2 gene was T/A 
cloned in pTZ57R/T vector (Invitrogen, 
San Diego, CA). Vectors were transformed 
into Escherichia coli TOP10F' competent 
cells using calcium chloride solution and 
under heat shock (42°C) for 90 sec. To 
screen recombinant vectors, competent 
cells were cultured in Luria broth (LB) agar 
(Merck Co., Germany) containing IPTG 
(0.1 M), ampicillin (100 µg/ml), and Xgal 
(20 mg/ml) at 37°C overnight. The white 
colonies were selected and cultured again in 
LB agar (containing ampicillin) at 37°C 
overnight. The recombinant vectors were 
extracted from bacterial cells by Plasmid 
Mini Extraction Kit (Bioneer, South Korea) 
according to the manufacturer’s 
instructions and PCR was conducted to 
confirm cloning. The concentrations of 
extracted plasmids were measured 
spectrophotometrically using a Nanodrop 
system (Implen Nano Photometer™, 
Germany). The plasmid copy number was 
calculated according to the size of the 
original plasmid alongside the cloned 
inserts and the concentration of the 
construct was calculated by the following 
formula:  
Number of copies/μl = (6.02 × 
1023copies × plasmid concentrations 
(g/μl))/ (Number of bases pairs × 660 
daltons/base) (Godornes et al., 2007). 
To plot standard curves, ten-fold serial 
dilutions of the plasmid were prepared and 
the M2 gene in plasmids was amplified in 
triplicate for each standard dilution point. 
Real time RT-PCR quantification was done 
and the expression of the gene was 
measured. 
 
Hemagglutination inhibition (HI) assay 
The HI assay was used to investigate the 
effect of the extract on influenza virus 
hemagglutinin (Abdal Dayem et al., 2015). 
Briefly, 50 μl of two-fold serial dilutions of 
the extract were diluted in PBS containing 
0.1% BSA mixed with 50 μl of the virus in 
PBS containing 0.1% BSA. After 1 hr of 
incubation, the HI assay was carried out to 
measure virus titration. Titers were 
expressed as HA units/50 μl (HAU/50 μl) in 
comparison with the control treatment 
(virus without extract). 
 
Western blot analysis 
MDCK cells in 6-well plates were 
inoculated with PR8 at 100 TCID50 in the 
presence of crude extract (30 and 15 µg/ml) 
for 24 hr at 37°C. The culture medium was 
removed and cells were washed twice with 
cold PBS and lysed in ice-cold 
radioimmunoprecipitation assay buffer 
(6X) containing a protease inhibitor 
cocktail. Protein concentration was 
measured by Bradford assay (BioRad), and 
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equal amounts of protein from each sample 
underwent blotting.  
The protein lysates were mixed with 
SDS loading buffer (0.125 M Tris-HCl 4%, 
SDS 20%, glycine 10%, and 2-mercapto-
ethanol), boiled for 5 min, separated by 
12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS–
PAGE) and transferred to polyvinylidene 
difluoride (PVDF; Bio-Rad, USA) 
membrane using semi-dry transfer system 
(Bio-Rad, USA). Viral nucleoprotein (NP), 
M1 protein, and cellular β-actin protein 
(loading control) were detected using anti-
NP (Thermo Fisher Scientific, USA), anti-
M1 (Thermo Fisher Scientific, USA) and β-
actin antibodies (Abcam; USA), 
respectively. The horseradish peroxidase 
conjugated secondary antibodies (goat anti-
rabbit/IgG) were used and the bound 
antibodies were detected using C-DiGit® 
Blot Scanner (LI-COR, USA). 
 
Statistical analysis 
Data analysis was conducted by SPSS 
software (Ver. 16). Kruskal-Wallis test was 
used to investigate intergroup differences. 
A p value<0.05 was considered statistically 
significant. 
 
 
Results 
PPE affects an early stage of virus 
infection  
To determine the stage of viral cycle 
where the extract exhibited its activity, 
time-of-drug-addition assays were 
performed on one cycle of influenza virus 
replication. The measurements of virus titer 
showed that virus titer decreased most 
markedly when the compound was present 
in the system during the whole test. In 
addition, the virus titer decreased 
significantly at time points (-1 hr) to 0 and 
0 to 2 hr (Figure 1). 
 
PPE inhibits viral protein synthesis  
The levels of influenza viral mRNA in 
the crude extract-treated and untreated 
infected cells were compared. RNA 
extraction was conducted at 13 hr after 
infection with influenza virus, and then the 
measurements of the intracellular influenza 
vmRNA (NS1, NP, HA and M2 genes) 
levels were performed. Quantitative real-
time PCR showed a significant and dose 
dependent decrease of influenza mRNA 
expression level in the crude extract-treated 
cells compared with untreated virus 
infected cells (p<0.05; Figure 2). 
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Figure 1. Time-of-addition activity of pomegranate 
peel extract on influenza virus. Influenza A virus 
was absorbed to MDCK cells (104 TCID50) for 1 hr. 
After washing non-absorbed virus, the crude extract 
was added at its maximum nontoxic concentration 
(30 µg/ml) to the cell-virus system at the following 
time points: -2 to -1 hr (before the adsorption of the 
virus), and -1 to 0 hr (adsorption) as well as at 
several time points post adsorption: 0–2, 2–4, and 4–
8 hr. Virus titer was determined after 8 hr of 
incubation in MDCK cells using TCID50 assay. 
 
To investigate viral protein synthesis in 
the cells after the inoculations of the virus, 
viral NP and M1 were studied using 
western blotting. We found that PPE 
inhibited the viral protein synthesis in a 
dose-dependent manner (Figure 3). Results 
indicated that the PPE inhibited the viral 
protein synthesis.  
 
PPE inhibits viral RNA replication 
The synthesis of viral RNA in the cells 
treated with different concentrations of PPE 
and untreated cells was compared 13 hr 
after the inoculation of the virus. The 
effects of the extract on the levels of viral 
RNA load were calculated using absolute 
quantification and shown as log10 copy 
number decrements in treatments.  
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Figure 2. Effects of pomegranate peel extract on the expression of viral mRNA in MDCK cells. Cells were infected 
with Influenza A virus and treated with different concentrations (30, 10, and 3 µg/ml) of the extract.  Total RNA 
was extracted 13 hr after influenza virus infection and the intracellular levels of mRNA influenza genes (NS1, 
NP, M1, and HA) were measured. Influenza virus mRNA levels were normalized by GAPDH. The data are the 
mean values of 2 independent repeats in duplicate (mean±SD). **p<0.01 comparison with the virus untreated 
sample using Kruskal Wallis test. 
 
 The quantitative analysis of influenza virus 
M2 gene revealed statistically significant 
and dose-dependent decrements in viral 
load when compared to the virus sample 
(Table 2).  
 
PPE does not have virucidal activity  
To investigate the antiviral action 
mechanism of the extract, a series of tests 
were conducted to examine its virucidal 
property and cellular localization. Results 
showed that virus yield in the extract and 
control groups was 4.9±0.56 and 5.08±0.59 
(log 10-TCID50), respectively (p>0.05). 
This confirmed that the extract did not exert 
any virucidal effect. 
 
Table 2.  Effects of PPE on the viral RNA copy 
number. 
 
Samples 
Ct 
(Mean±SD) 
Log10 Copy 
Numbers 
(Mean±SD) 
Virus control (untreated) 19.97±0.283 4.09±0.071 
Pomegranate 
peel treated 
30 (µg/ml) 30.05±0.947 1.55±0.238* 
10 (µg/ml) 25.24±0.092 2.77±0.023* 
3 (µg/ml) 22.66±0.0058 3.42±0.001 
 
Cells were infected with Influenza A virus and 
treated with different concentrations of pomegranate 
peel extract. Total RNA was extracted 13h after 
influenza virus infection and the Log10 copy 
numbers relating to Ct values of intracellular 
influenza M gene were measured. Data are averages 
of 2 independent repeats in duplicate. *significant 
decrease in comparison with the virus untreated 
sample (p< 0.05). 
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Figure 3. Effects of pomegranate peel extract on 
protein synthesis in MDCK cells. MDCK cells were 
infected with Influenza A virus and then incubated 
with different concentrations (15 and 30 µg/ml) of 
the extract for 24 hr at 37oC. The viral proteins, NP 
and M1, were detected using their specific primary 
antibodies and HRP-conjugated secondary 
antibodies. Cellular β-actin was used as a loading 
control. Well 1: virus control, well 2: virus + 15 
µg/ml crude extract, and well 3: virus + 30 µg/ml 
crude extract. 
 
PPE does not block the hemagglutination 
activity  
HI assay was used to determine whether 
PPE could prevent virus particles binding to 
cell surface receptors. The HI assay results 
indicated that pretreatment with the crude 
extract could not prevent the binding of this 
virus to RBCs (data not shown).  
 
 
Discussion 
P. granatum is a frequently used and 
important herb in folk medicine and its 
antibacterial, antiparasitic, apoptotic, 
antifungal, antiproliferative, and antiviral 
activities have been studied (Kim et al., 
2002; Reddy et al., 2007; Howell D'souza, 
2013). Few studies have reported the 
inhibitory effects of P. granatum fruit on 
herpes virus, influenza virus, poxviruses, 
and human immunodeficiency virus 
(Haidari et al., 2009; Howell D'souza, 
2013).   
In this study, the action mechanism of 
PPE was investigated against influenza 
A/PR/8 virus in MDCK cells. The results of 
time-of-drug-addition assay regarding one 
cycle of influenza virus replication showed 
that the greatest virus inhibition by PPE was 
seen at (-1) to 0 hr and 0 to 2 hr after 
infection. This finding may suggest that 
PPE inhibits the early step of influenza 
replication and virus adsorption but does 
not interfere with the virus binding to the 
receptors. Besides, our HI assay results 
indicated that PPE did not inhibit virus-
induced hemagglutination. In addition, PPE 
decreased influenza virus adsorption 
without influencing HA-mediated virus 
adsorption. Thus, two possible explanations 
for the impaired adsorption of influenza 
virus are; 1) PPE-mediated inactivation of 
the influenza virus neuraminidase (NA) 
protein, which cleaves sialic acid in the cell 
surface and promotes virus internalization 
(Ohuchi et al., 2006) and 2) PPE’s ability to 
induce physical damage to the virus 
particles, probably the lipid bilayers, which 
can lead to the loss of their hemifusion 
capacity. Anti-adsorption effects of this 
extract deserve further research. 
We clearly observed the ability of this 
extract in reducing the viral polymerase 
activity and RNA level. Time-of-drug-
addition assays also demonstrated that PPE 
inhibited influenza replication in the early 
step. It has been reported that before 2.5 hr, 
the NP and NS1 proteins are preferentially 
synthesized (Kummer et al., 2014). The 
expression of the NP becomes visible 2-4 hr 
after infection with strong nuclear 
accumulation (Shapiro et al., 1987). In 
influenza virus, the genomic RNAs 
(vRNAs) are associated with several copies 
of NPs and a few number of RNA-
dependent RNA polymerase complexes 
consisting of PA, PB1, and PB2, which 
integrate into ribonucleoprotein complex 
(RNP) that is necessary for the replication 
and transcription of the viral RNAs (Sugita 
et al., 2013). According to the current study, 
PPE may decrease the NP level and viral 
polymerase activity and consequently 
affect the activities of RNP complexes, 
leading to inhibition of both transcription 
and replication of the RNA level. 
Additional studies, however, should be 
conducted to identify the precise target of 
the extract throughout the influenza virus 
life cycle. 
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This study demonstrated that in vitro 
antiviral effect of PPE on influenza virus is 
most probably associated with inhibition of 
viral adsorption and viral RNA 
transcription. This extract should be also 
studied in clinical trials so that it can 
ultimately be used as a herbal drug against 
the influenza virus.  
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